The stock price of Biomarin Pharmaceutical Inc (NASDAQ: BMRN) has jumped by 0.80 compared to previous close of 66.13. Despite this, the company has seen a gain of 0.77% in its stock price over the last five trading days. prnewswire.com reported 2024-11-06 that UBS Global Healthcare Conference on November 12 at 11:00 am PST Jefferies London Healthcare Conference on November 19 at 9:00 am GMT 7th Annual Evercore ISI HealthCONx Conference on December 4 at 7:00 am PST SAN RAFAEL, Calif., Nov. 6, 2024 /PRNewswire/ — BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will present at three upcoming investor conferences.
Is It Worth Investing in Biomarin Pharmaceutical Inc (NASDAQ: BMRN) Right Now?
Biomarin Pharmaceutical Inc (NASDAQ: BMRN) has a price-to-earnings ratio that is above its average at 40.14x. The stock has a 36-month beta value of 0.30. Opinions on the stock are mixed, with 12 analysts rating it as a “buy,” 7 as “overweight,” 5 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for BMRN is 188.17M, and at present, short sellers hold a 2.86% of that float. On November 14, 2024, the average trading volume of BMRN was 1.75M shares.
BMRN’s Market Performance
BMRN stock saw a decrease of 0.77% in the past week, with a monthly decline of -5.39% and a quarterly a decrease of -25.25%. The volatility ratio for the week is 1.76%, and the volatility levels for the last 30 days are 1.95% for Biomarin Pharmaceutical Inc (BMRN). The simple moving average for the last 20 days is -2.05% for BMRN’s stock, with a simple moving average of -18.55% for the last 200 days.
Analysts’ Opinion of BMRN
Raymond James, on the other hand, stated in their research note that they expect to see BMRN reach a price target of $79. The rating they have provided for BMRN stocks is “Outperform” according to the report published on October 10th, 2024.
Bernstein gave a rating of “Outperform” to BMRN, setting the target price at $110 in the report published on August 20th of the current year.
BMRN Trading at -6.43% from the 50-Day Moving Average
After a stumble in the market that brought BMRN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -33.05% of loss for the given period.
Volatility was left at 1.95%, however, over the last 30 days, the volatility rate increased by 1.76%, as shares sank -4.99% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -25.82% lower at present.
During the last 5 trading sessions, BMRN rose by +0.77%, which changed the moving average for the period of 200-days by -25.62% in comparison to the 20-day moving average, which settled at $68.05. In addition, Biomarin Pharmaceutical Inc saw -30.86% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BMRN starting from Guyer Charles Greg, who proposed sale 5,278 shares at the price of $66.37 back on Nov 12 ’24. After this action, Guyer Charles Greg now owns shares of Biomarin Pharmaceutical Inc, valued at $350,324 using the latest closing price.
Burkhart Erin, the GVP, Chief Accounting Officer of Biomarin Pharmaceutical Inc, sale 714 shares at $90.00 during a trade that took place back on Aug 13 ’24, which means that Burkhart Erin is holding 14,449 shares at $64,260 based on the most recent closing price.
Stock Fundamentals for BMRN
Current profitability levels for the company are sitting at:
- 0.11 for the present operating margin
- 0.78 for the gross margin
The net margin for Biomarin Pharmaceutical Inc stands at 38.83. The total capital return value is set at 0.0. Equity return is now at value 6.25, with 4.74 for asset returns.
Based on Biomarin Pharmaceutical Inc (BMRN), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at 634.64. The debt to equity ratio resting at 0.0. The interest coverage ratio of the stock is 19.36.
Currently, EBITDA for the company is 310.28 million with net debt to EBITDA at 1170.77. When we switch over and look at the enterprise to sales, we see a ratio of 221.6. The receivables turnover for the company is 0.0for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.27.
Conclusion
To sum up, Biomarin Pharmaceutical Inc (BMRN) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
